comscoreASCO 2019: Women Don't Need Reminders to Take Aromatase Inhibitors, They Need Better Treatments for Side Effects

ASCO 2019: Women Don't Need Reminders to Take Aromatase Inhibitors, They Need Better Treatments for Side Effects

Dr. Dawn Hershman discusses results from a study looking at whether text messaging could increase the number of women who stick to their aromatase inhibitor treatment plans.
Jun 14, 2019
00:00
Download
00:00

At this ASCO annual meeting, Dr. Hershman presented results from a study looking at whether text messaging could increase the number of women who stick to their aromatase inhibitor treatment plans.

Listen to the podcast to hear Dr. Hershman talk about:

  • the background of the study

  • the study results, which showed no difference in treatment adherence between women who received text messages and women who didn't

  • what future research needs to do to better help women stick to their aromatase inhibitor treatment plans

About the guest
 
dawn hershman headshot
Dawn L. Hershman, MD

Affiliations: Columbia University Herbert Irving Comprehensive Cancer Center, American Society of Clinical Oncology, SWOG

Areas of specialization: breast cancer, medical oncology, cancer population science

Dr. Dawn Hershman is professor of medicine and epidemiology at Columbia
University. She also serves as leader of the Breast Cancer Program at the Herbert Irving Comprehensive Cancer Center at Columbia and is nationally recognized for her expertise in breast cancer treatment, prevention, and survivorship. A member of the Breastcancer.org Professional Advisory Board, Dr. Hershman also has conducted extensive research on breast cancer treatment and quality of life — she has published more than 250 scientific papers and has received the Advanced Clinical Research Award in Breast Cancer from the American Society of Clinical Oncology and the Advanced Medical Achievement Award from the Avon Foundation. Dr. Hershman is also on the editorial board of the Journal of Clinical Oncology and is an associate editor at the Journal of the National Cancer Institute.

— Last updated on July 31, 2022, 10:20 PM

 
Lilly

This content made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate